February 28, 2017 06:43 AM EST

Genentech doubles down on its PhIII Alzheimer’s campaign for crenezumab

John Carroll

Editor & Founder

Roche’s big biotech group Genentech is doubling down on one of the most prominent drugs in late-stage development for Alzheimer’s. The company is launching a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Genentech doubles down on its PhIII Alzheimer’s campaign for crenezumab

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Genen­tech dou­bles down on its PhI­II Alzheimer’s cam­paign for crenezum­ab

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Genentech doubles down on its PhIII Alzheimer’s campaign for crenezumab